229 related articles for article (PubMed ID: 12380950)
1. Multiple myeloma: role of allogeneic transplantation.
Pandit S; Vesole DH
Oncology (Williston Park); 2002 Sep; 16(9):1268-74; discussion 1274-6. PubMed ID: 12380950
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
4. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
[TBL] [Abstract][Full Text] [Related]
5. Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation.
Kröger N
Leukemia; 2007 Sep; 21(9):1851-8. PubMed ID: 17568819
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
Reynolds C; Ratanatharathorn V; Adams P; Braun T; Silver S; Ayash L; Carson E; Eisbruch A; Dawson LA; McDonagh K; Ferrara J; Uberti J
Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
[TBL] [Abstract][Full Text] [Related]
7. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow transplantation for multiple myeloma: where we are today.
Huff CA; Jones RJ
Curr Opin Oncol; 2002 Mar; 14(2):147-51. PubMed ID: 11880703
[TBL] [Abstract][Full Text] [Related]
10. The current status of hematopoietic stem cell transplantation for multiple myeloma.
Bensinger WI
Clin Adv Hematol Oncol; 2004 Jan; 2(1):46-52. PubMed ID: 16163159
[TBL] [Abstract][Full Text] [Related]
11. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect.
Zeiser R; Finke J
Eur J Cancer; 2006 Jul; 42(11):1601-11. PubMed ID: 16759847
[TBL] [Abstract][Full Text] [Related]
13. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hematopoietic cell transplantation for multiple myeloma.
Bensinger WI
Biomed Pharmacother; 2002 May; 56(3):133-8. PubMed ID: 12046684
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic bone marrow transplantation for multiple myeloma.
Ballester OF
Semin Oncol; 1993 Oct; 20(5 Suppl 6):67-71. PubMed ID: 8211218
[TBL] [Abstract][Full Text] [Related]
16. Evolving transplant options for multiple myeloma: autologous and nonmyeloablative allogenic.
Gibson J; Ho PJ; Joshua D
Transplant Proc; 2004 Oct; 36(8):2501-3. PubMed ID: 15561295
[TBL] [Abstract][Full Text] [Related]
17. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
Bacigalupo A; Sormani MP; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; di Grazia C; Dominietto A; Tedone E; Piaggio G; Podesta M; Bruno B; Oneto R; Lombardi A; Frassoni F; Rolla D; Rollandi G; Viscoli C; Ferro C; Garbarino L; Van Lint MT
Haematologica; 2004 Oct; 89(10):1238-47. PubMed ID: 15477210
[TBL] [Abstract][Full Text] [Related]
18. Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.
Kortüm M; Knop S; Einsele H
Future Oncol; 2011 Jan; 7(1):135-43. PubMed ID: 21174544
[TBL] [Abstract][Full Text] [Related]
19. [Allogeneic bone marrow transplantation for refractory multiple myeloma: presence of a graft-versus-myeloma effect].
Nawa Y; Noguchi T; Kojima K; Hara M
Rinsho Ketsueki; 2001 Jun; 42(6):481-7. PubMed ID: 11505527
[TBL] [Abstract][Full Text] [Related]
20. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.
Maury S; Lemoine FM; Hicheri Y; Rosenzwajg M; Badoual C; Cheraï M; Beaumont JL; Azar N; Dhedin N; Sirvent A; Buzyn A; Rubio MT; Vigouroux S; Montagne O; Bories D; Roudot-Thoraval F; Vernant JP; Cordonnier C; Klatzmann D; Cohen JL
Sci Transl Med; 2010 Jul; 2(41):41ra52. PubMed ID: 20650872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]